Sat, Aug 30, 2014, 6:34 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • mining_phd mining_phd Dec 1, 2012 6:01 PM Flag

    The difference between SNSS and CYCC longs.

     

    SNSS is going for refractory AML. SAPA is going for front line AML and is being identified as a possible "maintenance agent". At ASH, late stage data of the SAPA/DAC pilot arm will be reported. This data will demonstrate SAPA's efficacy/ survivability at the end of the curve. If we have survivors this far out, it would be very exciting indeed. If this data is strong, I doubt patients would migtrate away from SAPA/DAC to Vasoroxin due to the mucco-cystic oral lesions it causes, higher toxicity, and IV administration. CYCC will get the main coarse and SNSS will be eating scaps.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • you nailed it my friend...

    • Vosaroxin is spelled this way and not the way you did in the fraud post above and vosaroxin for AML treatment has 2 phases, called induction and consolidation. Induction is the phase where the aim is to bring or induce your leukemia into remission (where leukemia is not detectable). Consolidation treatment can be given after your study doctor tells you that your leukemia is in remission. The aim of consolidation is to destroy any remaining leukemia cells. You may complete up to 4 cycles of therapy that can include 2 cycles of induction therapy, called induction 1 and induction 2, and up to 2 cycles of consolidation therapy, called consolidation 1 and 2. A cycle is 2 to 8 weeks, with 5 days of treatment followed by at least 9 days and up to 51 days without treatment to allow your blood cells to recover. In some cases, induction cycles can be as long as 12 weeks. The time for a cycle can depend on how your leukemia responds to the treatment, how quickly your bone marrow grows back normal blood cells after treatment, and if your study doctor feels it is okay for you to begin another cycle.

      CYCC's drug SAPA is far more complicated: 1st part Odd cycles-decitabine by vein-1 hr-5 days-3 wks no drug Even cycles-sapacitabine by mouth twice a day-3 days-2 wks-2 wks no drug 2nd part If decitabine & sapacitabine is thought safe pts will be on 1 of these arms: Arm A: sapacitabine & decitabine Odd cycles-decitabine by vein-1 hr-5 days-3 wks no drug Even cycles-sapacitabine by mouth twice a day-3 days-2 wks-2 wks no drug Arm B: sapacitabine All cycles-sapacitabine by mouth twice a day-3 days-2 wks-2 wks no drug Arm C: decitabine All cycles-decitabine by vein-1 hr for 5 days then 3 wks no drug If decitabine & sapacitabine is thought unsafe, pts will be on 1 of these arms: Arm B: sapacitabine All cycles-sapacitabine by mouth twice a day for 3 days for 2 wks then 2 wks no drug Arm C: decitabine, azacitidine or low-dose ara-C-study doctors choice Decitabine-by vein-1 hr for 5 days then 3 wks no drug Azacitidine-under the skin daily for 7 days then 3 wks no drug Ara-C-under the skin twice a day for 10 days then 18 days no drug.

      The fact is they don't compete with each other!!!!

    • % Held by SNSS Insiders: 51.73%
      % Held by CYCC Insiders: 4.45%

      Even the CYCC insiders know they have an inferior product

    • Physicians are noting that vosaroxin likely will extend beyond the refractory AML setting such as first line settings when patients are at high risk of relapse or have cardiovascular issues

      You're out of touch with the true workings of both drugs.

 
SNSS
7.49-0.29(-3.73%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.